Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
43 hedge funds and large institutions have $67.3M invested in Sinovac Biotech, Ltd in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 21 reducing their positions, and 5 closing their positions.
8% more capital invested
Capital invested by funds: $62.3M → $67.3M (+$5.05M)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
4% less funds holding
Funds holding: 45 → 43 (-2)
11% less call options, than puts
Call options by funds: $76K | Put options by funds: $85K
43% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$664K |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$591K |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$199K |
| 4 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
+$177K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$46.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$457K |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$399K |
| 3 |
Morgan Stanley
New York
|
-$309K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$293K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$263K |
SVA Hedge Fund Activity: Q4 2014 in Review
43 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2014, worth a combined $67.3M — up 8.1% from $62.3M a quarter earlier.
Fund positioning in SVA was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 12 added to existing stakes and 21 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $664K. The largest seller was Renaissance Technologies, cutting an estimated $457K.
- 43 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2014, down from 45 in Q3 2014.
- Funds reported $67.3M of Sinovac Biotech, Ltd stock for Q4 2014, up 8.1% quarter-over-quarter.
- 5 funds opened new Sinovac Biotech, Ltd positions in Q4 2014 and 5 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q4 2014 was Wellington Management Group, an estimated $664K added.
- The largest Sinovac Biotech, Ltd seller in Q4 2014 was Renaissance Technologies, an estimated $457K sold.
Based on aggregated 13F filings for Q4 2014.